Interações de Bromocriptina

Do not use almotriptan tablets within 24 hours of an ergotamine-containing, or ergot-type medication, or of another 5-HT 1 agonist, e.g., another triptan ( 4.5 , 4.6 ) (bula de Almotriptana, Contraindicações)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (bula de Bromocriptina, Advertências e precauções)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (bula de Bromocriptina, Advertências e precauções)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (bula de Bromocriptina, Advertências e precauções)

Avoid use of MARCAINE WITH EPINEPHRINE concomitantly with ergot-type oxytocic drugs [see Drug Interactions (7.3)]. (bula de Bupivacaína, Advertências e precauções)

Avoid use of MARCAINE WITH EPINEPHRINE concomitantly with ergot-type oxytocic drugs [see Drug Interactions (7.3) ] . (bula de Bupivacaína + epinefrina, Advertências e precauções)

Use of bromocriptine, another dopamine agonist for this unapproved use has been associated with cases of hypertension, stroke, myocardial infarction, seizures, and death. (bula de Cabergolina, Advertências e precauções)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (bula de Bromocriptina, Advertências e precauções)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

Vasopressors should not be used in the presence of ergot-type oxytocic drugs, since a severe persistent hypertension may occur. (bula de Cloroprocaína, Advertências)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (bula de Bromocriptina, Advertências e precauções)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (bula de Bromocriptina, Advertências e precauções)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (bula de Bromocriptina, Advertências e precauções)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

• Recent use (i.e., within 24 hours) of another 5-hydroxytryptamine 1 (5-HT 1 ) agonist, ergotamine-containing medication, or ergot-type medication such as dihydroergotamine (DHE) or methysergide [see Drug Interactions (7.1) ] . (bula de Eletriptana, Contraindicações)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (bula de Bromocriptina, Advertências e precauções)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, an ergotamine containing or ergot-type medication such as dihydroergotamine (DHE) or methysergide [see Drug Interactions (7.1 , 7.2) ]. (bula de Frovatriptana, Contraindicações)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (bula de Bromocriptina, Advertências e precauções)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (bula de Bromocriptina, Advertências e precauções)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

Avoid use of FLAVALTA concomitantly with ergot-type oxytocic drugs [see Drug Interactions (7.3) ]. (bula de Lidocaína + epinefrina, Advertências e precauções)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (bula de Bromocriptina, Advertências e precauções)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (bula de Bromocriptina, Advertências e precauções)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (bula de Bromocriptina, Advertências e precauções)

Mepivacaine with epinephrine or other vasopressors should not be used concomitantly with ergot-type oxytocic drugs, because a severe persistent hypertension may occur. (bula de Mepivacaína, Advertências)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (bula de Bromocriptina, Advertências e precauções)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

…Ischemic bowel disease [see Warnings and Precautions (5.5)] Uncontrolled hypertension [see Warnings and Precautions (5.8)] Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions (7.1, 7.2)] Hypersensitivity to naratriptan tablets (angioedema… (bula de Naratriptana, Contraindicações)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

Therefore, patients receiving sublingual nitroglycerin should avoid ergotamine and related drugs or be monitored for symptoms of ergotism if this is not possible. (bula de Nitroglicerina, Interações medicamentosas)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (bula de Bromocriptina, Advertências e precauções)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (bula de Bromocriptina, Advertências e precauções)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (bula de Bromocriptina, Advertências e precauções)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (bula de Bromocriptina, Advertências e precauções)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (bula de Bromocriptina, Advertências e precauções)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (bula de Bromocriptina, Advertências e precauções)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (bula de Bromocriptina, Advertências e precauções)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (bula de Bromocriptina, Advertências e precauções)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (bula de Bromocriptina, Advertências e precauções)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions (7.2 and 7.3) ] . (bula de Rizatriptana, Contraindicações)

Also, there are limited clinical trial data supporting the safety of selective 5-hydroxytryptamine 1B (5-HT 1B ) agonists (e.g., sumatriptan) used concurrently with CYCLOSET, and the concomitant use of these agents with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

Also, there are limited clinical trial data supporting the safety of selective 5-hydroxytryptamine 1B (5-HT 1B ) agonists (e.g., sumatriptan) used concurrently with CYCLOSET, and the concomitant use of these agents with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (bula de Bromocriptina, Advertências e precauções)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (bula de Bromocriptina, Advertências e precauções)

Tolcapone tablets is also contraindicated in patients with a history of nontraumatic rhabdomyolysis or hyperpyrexia and confusion possibly related to medication (see PRECAUTIONS: Events Reported With Dopaminergic Therapy ). (bula de Tolcapona, Contraindicações)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (bula de Bromocriptina, Advertências e precauções)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (bula de Bromocriptina, Interações medicamentosas)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (bula de Bromocriptina, Advertências e precauções)

…bowel disease [see Warnings and Precautions ( 5.5 ) ] Uncontrolled hypertension [see Warnings and Precautions ( 5.8 ) ] Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions ( 7.1 , 7.3 ) ] Concurrent administration of a monoamine… (bula de Zolmitriptana, Contraindicações)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (bula de Bromocriptina, Interações medicamentosas)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (bula de Bromocriptina, Interações medicamentosas)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (bula de Bromocriptina, Interações medicamentosas)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Impulse Control/Compulsive Behaviors There have been reports of patients experiencing intense urges to gamble, increased sexual urges, intense urges to spend money uncontrollably, and/or other intense urges, and the inability to control these urges while taking one or more of the medications, including bromocriptine, that increase central dopaminergic tone. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (bula de Bromocriptina, Interações medicamentosas)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (bula de Bromocriptina, Interações medicamentosas)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (bula de Bromocriptina, Interações medicamentosas)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (bula de Bromocriptina, Interações medicamentosas)

The risk of hypertension is increased if bupropion hydrochloride extended-release tablets (XL) are used concomitantly with MAOIs or other drugs that increase dopaminergic or noradrenergic activity [see Contraindications (4)] . (bula de Bupropiona, Advertências e precauções)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (bula de Bromocriptina, Interações medicamentosas)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (bula de Bromocriptina, Interações medicamentosas)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (bula de Bromocriptina, Interações medicamentosas)

Impulse Control/Compulsive Behaviors There have been reports of patients experiencing intense urges to gamble, increased sexual urges, intense urges to spend money uncontrollably, and/or other intense urges, and the inability to control these urges while taking one or more of the medications, including bromocriptine, that increase central dopaminergic tone. (bula de Bromocriptina, Advertências e precauções)

Impulse Control/Compulsive Behaviors There have been reports of patients experiencing intense urges to gamble, increased sexual urges, intense urges to spend money uncontrollably, and/or other intense urges, and the inability to control these urges while taking one or more of the medications, including bromocriptine, that increase central dopaminergic tone. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (bula de Bromocriptina, Interações medicamentosas)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (bula de Bromocriptina, Interações medicamentosas)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (bula de Bromocriptina, Interações medicamentosas)

Rarely, prolonged daily use of other ergot alkaloid drugs has been associated with cardiac valvular fibrosis. (bula de Di-hidroergotamina, Advertências)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (bula de Bromocriptina, Interações medicamentosas)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (bula de Bromocriptina, Interações medicamentosas)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (bula de Bromocriptina, Interações medicamentosas)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (bula de Bromocriptina, Interações medicamentosas)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (bula de Bromocriptina, Interações medicamentosas)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (bula de Bromocriptina, Interações medicamentosas)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Agonistic Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. (bula de Fenilefrina, Interações medicamentosas)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (bula de Bromocriptina, Interações medicamentosas)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (bula de Bromocriptina, Interações medicamentosas)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (bula de Bromocriptina, Interações medicamentosas)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (bula de Bromocriptina, Interações medicamentosas)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (bula de Bromocriptina, Interações medicamentosas)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Bromocriptine : Lanreotide Injection may increase the absorption of bromocriptine. (bula de Lanreotida, Interações medicamentosas)

Impulse Control/Compulsive Behaviors There have been reports of patients experiencing intense urges to gamble, increased sexual urges, intense urges to spend money uncontrollably, and/or other intense urges, and the inability to control these urges while taking one or more of the medications, including bromocriptine, that increase central dopaminergic tone. (bula de Bromocriptina, Advertências e precauções)

Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. (bula de Lidocaína, Interações medicamentosas)

…hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7) and Clinical Pharmacology (12.3) ]. (bula de Linezolida, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (bula de Bromocriptina, Interações medicamentosas)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (bula de Bromocriptina, Interações medicamentosas)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (bula de Bromocriptina, Interações medicamentosas)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (bula de Bromocriptina, Interações medicamentosas)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (bula de Metilergometrina, Interações medicamentosas)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (bula de Bromocriptina, Interações medicamentosas)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (bula de Bromocriptina, Interações medicamentosas)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (bula de Bromocriptina, Interações medicamentosas)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (bula de Bromocriptina, Interações medicamentosas)

Dopaminergic Drugs (levodopa and amantadine): CNS toxicity can occur when used concomitantly with CONTRAVE. (bula de Naltrexona + bupropiona, Interações medicamentosas)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (bula de Bromocriptina, Interações medicamentosas)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Bromocriptine: dose adjustment of bromocriptine may be necessary (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (bula de Bromocriptina, Interações medicamentosas)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (bula de Bromocriptina, Interações medicamentosas)

Bromocriptine: Consider bromocriptine dose reduction. (bula de Pasireotida, Interações medicamentosas)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

CYP3A4 Substrates Refer to the Prescribing Information for a CYP3A substrate where minimal concentration changes may lead to serious adverse reactions (e.g. rivaroxaban, calcineurin inhibitors, ergot derivatives, tyrosine kinase inhibitors) for the recommended dosage modification and/or monitoring. (bula de Primaquina, Interações medicamentosas)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (bula de Bromocriptina, Interações medicamentosas)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (bula de Bromocriptina, Interações medicamentosas)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (bula de Bromocriptina, Interações medicamentosas)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

For this reason, prescribers should monitor patients for drowsiness or sleepiness, because some of the events occur well after initiation of treatment with dopaminergic medication. (bula de Rasagilina, Advertências e precauções)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (bula de Bromocriptina, Interações medicamentosas)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (bula de Bromocriptina, Interações medicamentosas)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (bula de Bromocriptina, Interações medicamentosas)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (bula de Bromocriptina, Interações medicamentosas)

Dyskinesia ZELAPAR may potentiate dopaminergic side effects of levodopa and may cause dyskinesia or exacerbate preexisting dyskinesia. (bula de Selegilina, Advertências e precauções)

• Drugs that could increase sirolimus blood concentrations: Bromocriptine, cimetidine, cisapride, clotrimazole, danazol, diltiazem, fluconazole, letermovir, protease inhibitors (e.g., HIV and hepatitis C that include drugs such as ritonavir, indinavir, boceprevir, and telaprevir), metoclopramide, nicardipine, troleandomycin, verapamil • Drugs and other agents… (bula de Sirolimo, Interações medicamentosas)

Drugs that Increase Blood Pressure and/or Heart Rate and Dopaminergic Drugs : Use caution when co-administering with SUNOSI. (bula de Solriamfetol, Interações medicamentosas)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (bula de Bromocriptina, Interações medicamentosas)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (bula de Bromocriptina, Interações medicamentosas)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (bula de Bromocriptina, Interações medicamentosas)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (bula de Bromocriptina, Interações medicamentosas)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (bula de Bromocriptina, Interações medicamentosas)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (bula de Bromocriptina, Interações medicamentosas)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with tetrabenazine tablets and other drugs that reduce dopaminergic transmission [see Drug Interactions (7.6) ]. (bula de Tetrabenazina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (bula de Bromocriptina, Interações medicamentosas)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Valbenazina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (bula de Bromocriptina, Interações medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

Ergot derivatives: dihydroergotamine ergotamine methylergonovine ↑ dihydroergotamine ↑ ergotamine ↑ methylergonovine Concomitant administration with dihydroergotamine, ergotamine or methylergonovine is not recommended. (bula de Bictegravir + entricitabina + tenofovir alafenamida, Interações medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

Falling Asleep During Activities of Daily Living and Somnolence Patients taking carbidopa-levodopa products alone or with other dopaminergic drugs have reported suddenly falling asleep without prior warning of sleepiness while engaged in activities of daily living (includes operation of motor vehicles). (bula de Carbidopa, Advertências)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

The expected incidence of these events, however, is so low that even if pramipexole caused these events at rates similar to those attributable to other dopaminergic therapies, it would be unlikely that even a single case would have occurred in a cohort of the size exposed to pramipexole in studies to date. (bula de Pramipexol, Advertências e precauções)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

Fibrotic Complications Cases of retroperitoneal fibrosis, pulmonary infiltrates, pleural effusion, pleural thickening, pericarditis, and cardiac valvulopathy have been reported in some patients treated with ergot-derived dopaminergic agents. (bula de Ropinirol, Advertências e precauções)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (bula de Bromocriptina, Interações medicamentosas)